Obesity Trial, Recruiting NCT06869941 Sponsor: Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta Condition: Obesity
Back to Obesity

Obesity Trial, Recruiting

NCT06869941
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults (men and women) who are older than 20 years of age
  • People who are already scheduled for a surgical procedure to remove fat tissue from the body
  • People who have given signed written consent to take part in the study

Who may not be able to join:

  • People who have serious health conditions not related to obesity, such as cancer or severe kidney or liver disease
  • People who have conditions involving ongoing inflammation throughout the body, such as rheumatoid arthritis, Crohn's disease, asthma, or long-term infections like HIV or tuberculosis — or any current infectious disease
  • Women who are pregnant or breastfeeding
  • People who are under any legal or administrative restrictions
  • People who have had signs or symptoms of an infection in the past month
  • People who have taken antibiotics, antifungal, or antiviral medications in the past 3 months
  • People who regularly use steroid or anti-inflammatory medications
  • People with a significant history of psychiatric illness
  • People who drink more than 40g of alcohol per day (women) or more than 80g per day (men), or who have a history of drug misuse
  • People currently taking immunosuppressant medications (drugs that lower the immune system's activity)
  • People with a severe eating disorder
  • People whose liver enzyme levels (GOT/GPT) are more than twice the normal upper limit, or who show clear signs of liver disease or hepatitis
  • People with a history of iron storage disorders, such as hereditary hemochromatosis or related conditions
  • People with certain kidney function measurements outside acceptable ranges (creatinine above 1.2 or a filtration rate below 40) (confirm with trial site)
  • People currently receiving treatment for cancer, except for certain types of minor skin cancers (basal cell or squamous cell)
  • People with significant heart disease classified as class III or IV, or known heart or cardiovascular disease caused by reduced blood supply
  • People with kidney failure, a history of kidney transplant, or who are currently on dialysis
  • People with chronic constipation, defined as going 7 or more days between bowel movements

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: José Manuel Fernández-Real, M.D., Ph.D., Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta

Phone: +34972940200

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
Registry
ClinicalTrials.gov
Start date
5 August 2025
Est. completion
31 January 2027

Where this trial is recruiting

🇪🇸 Spain

Primary endpoints

Glycemic variability; The percentage of time in glucose target range (glucose level 100mg/dl-125mg/dl); The glycaemic risk measured with the low blood glucose index (LBGI); The glycaemic variability measured with mean amplitude of glycaemic excursions (MAGE); Minutes light sleep; Minutes deep sleep; Minutes rapid eye movement (REM)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov